抑癌微小RNA参与恶性胸膜间皮瘤PD-L1表达调控
在72例接受胸膜切除术(伴或不伴剥脱术)的恶性胸膜间皮瘤(MPM)患者中,25%PD-L1免疫组化阳性,多见于非上皮样亚型(p=0.01)。PD-L1阳性者中位总生存4.0个月 vs 阴性者9.2个月(p<0.001),多因素分析HR=2.2(95%CI 1.2-4.1,p<0.01)。PD-L1阳性样本中miR-15b、miR-16、miR-193a-3p、miR-195、miR-200c中位表达水平显著降低;转染miR-15a、miR-16及miR-193a-3p模拟物可下调细胞系PD-L1 mRNA和蛋白。
要点
- 72例MPM中18例(25%)PD-L1阳性,非上皮样亚型更常见(p=0.01)。
- PD-L1阳性者中位总生存4.0个月 vs 阴性9.2个月(p<0.001),多因素HR=2.2(95%CI 1.2-4.1,p<0.01)。
- PD-L1阳性样本中miR-15b、miR-16、miR-193a-3p、miR-195、miR-200c中位表达水平显著降低。
核心结论
- 数据提示抑癌微小RNA参与MPM中PD-L1表达的调控。
研究设计与样本
- 对接受胸膜切除术(伴或不伴剥脱术)患者的组织芯片样本行PD-L1免疫组化分析,共72例MPM患者。
- 微小RNA表达采用逆转录定量聚合酶链反应分析;细胞系转染微小RNA模拟物和小干扰RNA后评估PD-L1调控。
- 微小RNA与PD-L1相互作用采用Argonaute-2免疫沉淀和荧光素酶报告基因实验分析。
主要发现
- 72例MPM中18例(25%)PD-L1染色阳性,非上皮样亚型中更常见(p=0.01)。
- PD-L1阳性者中位总生存4.0个月 vs 阴性者9.2个月(p<0.001)。
- 多因素分析中PD-L1表达仍为显著不良预后指标(HR=2.2,95%CI 1.2-4.1,p<0.01)。
- PD-L1阳性样本中miR-15b、miR-16、miR-193a-3p、miR-195、miR-200c的中位微小RNA表达水平显著降低。
- 转染miR-15a和miR-16模拟物(二者均被预测靶向PD-L1)使MPM细胞系PD-L1 mRNA和蛋白下调;含替代G-U靶位点的miR-193a-3p亦引起PD-L1下调。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The upregulation of programmed death ligand 1 (PD-L1) is found in many cancers and contributes to evasion of the host's immune defense. In malignant pleural mesothelioma (MPM), PD-L1 expression is associated with the nonepithelioid histological subtype and poor prognosis, but the pathways involved in control of PD-L1 expression in MPM are poorly understood. To address one possible means of PD-L1 regulation we investigated the relationship between dysregulated microRNA levels and PD-L1 expression. METHODS: PD-L1 expression was analyzed by immunohistochemistry in tissue microarrays prepared from samples from patients undergoing an operation (pleurectomy with or without decortication). MicroRNA expression was analyzed by reverse-transcriptase quantitative polymerase chain reaction. Regulation of PD-L1 expression in cell lines was assessed after transfection with microRNA mimics and small interfering RNAs. Interaction between microRNAs and PD-L1 was analyzed by using argonaute-2 immunoprecipitation and a luciferase reporter assay. RESULTS: In a series of 72 patients with MPM, 18 (25%) had positive PD-L1 staining, and this was more common in patients with the nonepithelioid subtype (p = 0.01). PD-L1 expression was associated with poor survival (median overall survival 4.0 versus 9.2 months with positive versus negative PD-L1 expression [p < 0.001]), and in multivariate analyses, PD-L1 expression remained a significant adverse prognostic indicator (hazard ratio = 2.2, 95% confidence interval: 1.2-4.1, p < 0.01). In the same patient series, PD-L1 expression was also associated with downregulation of microRNAs previously shown to have tumor suppressor activity in MPM. The median microRNA expression levels of miR-15b, miR-16, miR-193a-3p, miR-195, and miR-200c were significantly lower in the PD-L1-positive samples. Transfecting MPM cell lines with mimics corresponding to miR-15a and miR-16, both of which are predicted to target PD-L1, led to downregulation of PD-L1 mRNA and protein. In addition, miR-193a-3p, with an alternative G-U-containing target site, also caused PD-L1 downregulation. CONCLUSIONS: Together, these data suggest that tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in MPM.
引用
- Kao SC, Cheng YY, Williams M, et al. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma. J Thorac Oncol. 2017. PMID: 28629895. doi:10.1016/j.jtho.2017.05.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。